Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibiting menin attenuates high-fat diet–induced weight gain by limiting intestinal lipid absorption in mice
Xiaoru Cao, Pingping Zhou, Haiyue Meng, Zhitao Guo, Yan Cao, Chenghao Wang, Lulu Liu, Yinghao Guo, Yue Wang, Guoshun Xin, Dabin Liu, Feng Geng, Jian Ma
Xiaoru Cao, Pingping Zhou, Haiyue Meng, Zhitao Guo, Yan Cao, Chenghao Wang, Lulu Liu, Yinghao Guo, Yue Wang, Guoshun Xin, Dabin Liu, Feng Geng, Jian Ma
View: Text | PDF
Research Article Gastroenterology Metabolism

Inhibiting menin attenuates high-fat diet–induced weight gain by limiting intestinal lipid absorption in mice

  • Text
  • PDF
Abstract

Intestinal lipid metabolism is essential for systemic energy homeostasis, and its modulation is emerging as a therapeutic strategy for obesity. Menin, encoded by the MEN1 gene, is a scaffold protein that regulates chromatin remodeling and gene expression and is abundantly expressed in intestinal epithelial cells (IECs), but its metabolic role remains underexplored. Here, we generated IEC-specific Men1-knockout mice and found that Men1 deficiency protected against high-fat diet–induced obesity, accompanied by elevated carboxylesterase 1 (CES1) expression in IECs. Increased CES1 promoted triglyceride (TG) hydrolysis and reduced intracellular TG storage, thereby limiting the lipid substrate pool required for ApoB48-dependent chylomicron assembly. Although lipid hydrolysis was enhanced, steady-state free fatty acid levels were not increased; instead, Men1 deficiency activated fatty acid β-oxidation programs and increased etomoxir-sensitive fatty acid–dependent mitochondrial respiration, supporting enhanced fatty acid catabolism. Mechanistically, menin recruited histone deacetylase 1 and interacted with the nuclear receptor liver X receptor-β to suppress Ces1g transcription, thereby sustaining efficient intestinal lipid absorption. Pharmacological inhibition of menin with MI-463 recapitulated the metabolic effects of inducible Men1 deletion. In a human gut organoid-on-chip system, MI-463 dose-dependently increased CES1 expression and markedly reduced lipid accumulation. Collectively, our findings identify menin as a regulator of intestinal lipid metabolism and suggest menin inhibition as a potential therapeutic strategy for obesity-related metabolic disorders.

Authors

Xiaoru Cao, Pingping Zhou, Haiyue Meng, Zhitao Guo, Yan Cao, Chenghao Wang, Lulu Liu, Yinghao Guo, Yue Wang, Guoshun Xin, Dabin Liu, Feng Geng, Jian Ma

×

Figure 5

The menin–HDAC1–LXRβ complex cooperatively represses Ces1g/CES1 transcription.

Options: View larger image (or click on image) Download as PowerPoint
The menin–HDAC1–LXRβ complex cooperatively represses Ces1g/CES1 transcri...
(A) RT-qPCR of Men1 and Ces1g in MODE-K cells after shMen1 knockdown (KD). (B) Immunoblotting of menin and CES1 after Men1 KD or overexpression (OE). (C) ChIP-seq of menin at the Ces1g promoter in IECs. (D and E) ChIP-qPCR of menin and polymerase II (Pol II) occupancy at Ces1g promoter regions P4 and P5. (F) Ces1g promoter luciferase activity with or without menin overexpression. (G) Overlap of transcription factors associated with CES1 regulation, metabolism, and menin interaction. (H) Co-IP of Flag-menin with HA-tagged HNF4α, LXRα, LXRβ, PPARγ, or RELA. (I) CES1 promoter activity following transcription factor OE. (J) Ces1g promoter activity in MEN1 wild-type or knockout HEK293T cells expressing LXRβ or vector. (K) Activities of wild-type and double-mutant CES1 promoter reporters in control or Men1-KO cells expressing LXRβ or vector. (L) Men1, Abca1, and Ces1g expression in control or Men1-KO MODE-K cells treated with 2 μM GSK2033. (M) Genome-wide H3 acetylation profiles around transcription start sites (±2.5 kb) in Men1fl/fl and Men1ΔIEC IECs. (N) H3 acetylation tracks at the Ces1g locus. (O) Co-IP showing LXRβ association with menin, HDAC1, and HDAC3. (P) ChIP-qPCR analysis of H3Ac, H3K27Ac, HDAC1, HDAC3, and LXRβ occupancy at promoter region P5. (Q) Sequential ChIP showing co-occupancy of menin, LXRβ, and HDAC1 at the Ces1g promoter. (R) Model of LXRβ-mediated recruitment of the menin–HDAC1 complex to repress Ces1g transcription. For A, I, K, and L, n = 3; panels B, F, H, J, O, and Q show representative results from 3 independent experiments; for D, E, and P, n = 3 mice per group. All data are presented as mean ± SD. Statistical significance was assessed by 2-way ANOVA for panels A, D, E, L, and P and by 1-way ANOVA for panels F and I–K. *P < 0.05, **P < 0.01, ***P < 0.001. LXR, liver X receptor; HDAC, histone deacetylase; HNF, hepatocyte nuclear factor.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts